Orphan Status for Ibrutinib

Ibrutinib has been granted an orphan designation by the European Medicines Agency for the treatment of follicular lymphoma (FL).

Results from early studies in patients with FL indicated that ibrutinib may improve outcomes in patients whose disease has recurred or is no longer responding to treatment. The orphan designation requires additional studies be undertaken to demonstrate the therapy’s quality, safety and efficacy before marketing authorisation can be granted. For more information, click here.

 

Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe

WEIGH-IN WEDNESDAY

Do you understand how cancer drugs are approved in your country?

IN THE NODE

Updates

 

The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.